complement factor IGenealiases: AHUS3 · ARMD13 · C3BINA · C3b-INA · FI · IF
Q-omics provides the consensus-scored CFI profile across patient tissues and cancer cell-line models. CFI expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, CFI is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, CFI protein abundance shows 20,226 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LGG, KICH, and PDAC as cancer lineages where CFI shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CFI — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CFI survival associations across molecular data types. CFI RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CFI RNA expression–survival associations across cancer types. High CFI expression shows unfavorable associations in LGG, BLCA, GBM and LUSC, but favorable associations in MESO and SKCM. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for CFI RNA expression.
This table summarizes CFI tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CFI. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CFI shows lower tumor expression in KICH, LUSC, LIHC and BRCA and higher tumor expression in THCA and COAD. The KICH box plot shows higher CFI RNA expression in normal versus tumor tissue (log2 FC = −4.122, t-test p < 0.001).
This table shows molecular features associated with CFI in patient tissues and cancer cell lines. In patient samples, CFI shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, CFI RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and CNS.
